ImmuSAFE COVID Tests Product Range

KEY APPLICATIONS

ImmuSAFE™ can be utilised for vaccine clinical trials or sero-prevalence research studies.

Population antibody profiling for sero-prevalence research

The target epitope of antibodies produced following infection exhibit a significant level of diversity across a population. ImmuSAFE™ provides a more accurate determination of sero-prevalence by targeting over 10 different domains of SARS-CoV-2.

Determine the protective quality and quantity of antibodies produced

Some individuals produce antibodies that target locations which are neutralising (protective), whereas others produce non-neutralising antibodies. Identifying individuals who have high titres of potentially neutralising antibodies against SARS-CoV-2 that may protect against reinfection or provide indications as to whether booster vaccinations are required.

Enable quantitative assessment of patient response in vaccination trials

The determination of specific antigenic sites is crucial in vaccine development against COVID-19. The screening for immunoreactivity using the ImmuSAFE™ will facilitate the mass screening of COVID-19 samples for diagnosis and the identification of immunodominant epitopes, which is crucial for population-based (or even patient-centric) vaccine development.

ImmuSAFE™ is the world’s first multi-antigen biochip-based quantitative screening test for COVID-19

ImmuSAFE™ is a lab-based biochip test that utilises Sengenics’ patented KREX™ protein folding technology ensuring that viral antigens are correctly folded, preserving all conformational and linear antibody binding sites. More than ten domains of SARS-CoV-2 Nucleocapsid and Spike proteins including both full-length and numerous truncated versions are used in the tests.

Cross-reactivity between immunogenic regions of SARS-CoV-2 and other coronaviruses may lead to an overestimation of sero-prevalence in a given population. ImmuSAFE™ is designed to reduce cross-reactivity by targeting multiple SARS-CoV-2 specific domains, resulting in fewer false positives, and a more accurate determination of sero-prevalence.

The ImmuSAFE™ product range includes biochip-based tests that also incorporate additional viral antigens such as: SARS-CoV-2 Envelope, Nucleocapsid proteins from 13 other Coronaviruses including 5 human Coronaviruses (SARS-CoV, MERS-CoV, NL63, HKU1 and 229E) as well as Influenza A and B HA antigen subtypes. Content can be customised based on individualised requirements for vaccine clinical trials or sero-prevalence research studies.

Product Description


Code Product Description
39508H ImmuSAFE™ COVID+ Protein Microarray
Contains multiple SARS-CoV-2 specific domains (Nucleocapsid and Spike proteins) including full-length and numerous truncated versions. Key applications are vaccine clinical trials and sero-prevalence research studies.
Read More
39508V ImmuSAFE™ Respiratory Virus Protein Microarray
Contains multiple SARS-CoV-2 proteins, Nucleocapsid proteins from 5 other human Coronaviruses (SARS-CoV, MERS-CoV, NL63, HKU1 and 229E) as well as Influenza A and B HA antigen subtypes. Key application is sero-prevalence research studies.
39508R ImmuSAFE™ Discovery Virus Protein Microarray
Contains multiple SARS-CoV-2 proteins, Nucleocapsid proteins from 13 other Coronaviruses including 5 human Coronaviruses (SARS-CoV, MERS-CoV, NL63, HKU1 and 229E) as well as Influenza A and B HA antigen subtypes. Key application is for research and development purposes.
COVID-19 Antigens
All antigens are expressed in sf9 insect cells using the patented KREX functional proteomics technology. Viral antigens are full-length, correctly folded, functional, with both conformational and non-conformational antibody binding sites preserved. Each antigen is supplied as either lysate or purified protein.
Read More


FEATURED PRODUCTS

IMMUNOME Protein Array

High-throughput multiplexed autoantibody screening protein array containing 1600+
autoantigens

ImmuSAFE COVID Tests

Contains correctly folded antigens from SARS-CoV-2 and 25 other Corona and Influenza
viruses

SARS-CoV-2 Antigens

7 Recombinant SARS-CoV-2 antigens expressed using the patented KREX™ functional proteomics technology

DOWNLOADS

Resources to access our technology

FAQs

Your technical questions – answered

SOLUTIONS

One technology – endless possibilities

Sengenics - Functional Proteomics | Krex Technology | Protein Array Supplier

Sengenics is a functional proteomics company that leverages its patented KREX technology for production of full-length, correctly folded and functional proteins. The key application of KREX is the discovery of autoantibody biomarkers for two core medical use cases:  stratification of patients undergoing treatment with autoimmune or cancer drugs and identification of autoantibody biomarkers that may be used to diagnose cancer, autoimmune or neurodegenerative conditions. Some autoantibodies that are identified as diagnostic biomarkers may be protective and have potential in themselves as therapeutic biomolecules.

Find Us On:

2008 – 2020© Sengenics All rights reserved | Sengenics Corporation Pte Ltd. Registered in Singapore no. 201734100D | Sengenics UK Ltd. Registered in England and Wales No 11016361 

X